Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal

Summary by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.

1 Articles

MarketBeatMarketBeat
Center

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal

PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Sunday, August 16, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Bankruptcy icon

Bankruptcy

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal